Venous thromboembolism is a risk with several contemporary HRT formulations, consistent with earlier data. Several ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Lack of transparency in early studies and manufacturer summaries are among the issues uncovered during litigation.

An echo analysis highlights changes in the right ventricle that contribute to patient’s improved QoL with tricuspid TEER.

News from the American Heart Association 2024 Scientific Sessions took seven of the 10 top slots this month.

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE ...

For the last decade, Erin D. Michos, MD (Johns Hopkins University School of Medicine, Baltimore, MD), has consistently posted updates to her feed on X (formerly Twitter) for her more than 30,000 ...